Paul D. Kemmitt
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Catalytic C–H Functionalization Methods, Catalytic Cross-Coupling Reactions, Crystallography and molecular interactions
Most-Cited Works
- → Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor(2014)591 cited
- → Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6(2018)136 cited
- → Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy(2021)90 cited
- → Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C(2020)83 cited
- → Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors(2017)78 cited
- → Discovery of a Potent, Selective, and Orally Efficacious Pyrimidinooxazinyl Bicyclooctaneacetic Acid Diacylglycerol Acyltransferase-1 Inhibitor(2009)75 cited
- → Making medicinal chemistry more effective—application of Lean Sigma to improve processes, speed and quality(2009)69 cited
- → Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C(2022)60 cited
- → 1—Azatriene cyclisation as a route to annelated pyrido[4,3-b]indoles(1997)49 cited
- → Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers(2016)47 cited